Relation-Aware Equivariant Graph Networks for Epitope-Unknown Antibody Design and Specificity Optimization
Lirong Wu, Haitao Lin, Yufei Huang, Zhangyang Gao, Cheng Tan, Yunfan Liu, Tailin Wu, Stan Z. Li
TL;DR
This work tackles the problem of designing antigen-specific antibody CDRs when epitopes are unknown and specificity must be preserved. It introduces RAAD, a one-shot framework based on an Attributed Heterogeneous Graph (AHG) and Relation-Aware Equivariant Graph Networks (RA-EGN) to jointly model sequence and structure while dynamically updating antigen–antibody interactions through multiple edge relations. A new SP-score is proposed to quantify specificity, augmented by a contrastive mutual-information loss and Iterative Target Augmentation to steer optimization toward target selectivity without sacrificing realism. Across extensive experiments on SAbDab and RAbD benchmarks, RAAD outperforms state-of-the-art baselines in CDR sequence/structure modeling, antigen-binding CDR-H3 generation, and specificity optimization, demonstrating strong robustness to CDR length and input context and highlighting the practical potential for epitope-unknown antibody design.
Abstract
Antibodies are Y-shaped proteins that protect the host by binding to specific antigens, and their binding is mainly determined by the Complementary Determining Regions (CDRs) in the antibody. Despite the great progress made in CDR design, existing computational methods still encounter several challenges: 1) poor capability of modeling complex CDRs with long sequences due to insufficient contextual information; 2) conditioned on pre-given antigenic epitopes and their static interaction with the target antibody; 3) neglect of specificity during antibody optimization leads to non-specific antibodies. In this paper, we take into account a variety of node features, edge features, and edge relations to include more contextual and geometric information. We propose a novel Relation-Aware Antibody Design (RAAD) framework, which dynamically models antigen-antibody interactions for co-designing the sequences and structures of antigen-specific CDRs. Furthermore, we propose a new evaluation metric to better measure antibody specificity and develop a contrasting specificity-enhancing constraint to optimize the specificity of antibodies. Extensive experiments have demonstrated the superior capability of RAAD in terms of antibody modeling, generation, and optimization across different CDR types, sequence lengths, pre-training strategies, and input contexts.
